Crisafulli, Salvatore http://orcid.org/0000-0001-9622-169X
Sultana, Janet
Fontana, Andrea
Salvo, Francesco
Messina, Sonia
Trifirò, Gianluca
Funding for this research was provided by:
PTC Therapeutics
Article History
Received: 13 December 2019
Accepted: 28 May 2020
First Online: 5 June 2020
Ethics approval and consent to participate
: Not applicable.
: Not applicable.
: G. Trifirò has served on advisory boards for Sandoz, Hospira, Sanofi, Biogen, Ipsen, and Shire and is a consultant for Otsuka. G Trifirò is the principal investigator of observational studies funded by several pharmaceutical companies (e.g. Amgen, AstraZeneca, Daiichi Sankyo and IBSA) to University of Messina, as well as scientific coordinator of the Master’s program ‘Pharmacovigilance, pharmacoepidemiology and pharmacoeconomics: real-world data evaluations’ at University of Messina, which is partly funded by several pharmaceutical companies. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.